Europe Exosome Therapeutic Market – Industry Trends and Forecast to 2030

Europe Exosome Therapeutic Market, By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine, Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of Administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research and Academic Institutes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.

Europe Exosome Therapeutic Market Analysis and Size

Exosomes are tiny membrane sacs/vesicles that can be engineered to deliver varied therapeutic payloads, containing chemotherapeutic agents, antisense oligonucleotides, and immune modulators. They contain receptors for viruses that make recipient cells susceptible to virus entry. Exosomes have characteristics like regeneration and stability and lower the immune function by causing activated cytotoxic T cells to die. The rise in the prevalence of chronic disorders such as cancer and rising healthcare expenditure are the major factors influencing the market growth rate. Furthermore, the growing demand or need for screening and diagnosing, technological advancement associated with exosomes, and the rising introduction of the explicit system for the study of the proteins particular to exosomes are the factors that will expand the exosome therapeutic market. Rising demand for more development and research activities which are further supported by the government organization policy across the globe, will positively impact the market growth rate. However, many technical difficulties, such as optimization of purification, increasing the homogeneity of exosomes, and efficient transfection strategies, are the factors that will hinder market growth. Lack of awareness, the cumbersome nature of the methods for isolation/purification, and the dearth of skilled professionals will further challenge the exosome therapeutic market in the forecast period.

Data Bridge Market Research analyzes that the Europe exosome therapeutic market, which was USD 13.69 million in 2022, would rocket up to USD 59.99 million by 2030, and is expected to undergo a CAGR of 18.05% during the forecast period 2023 to 2030. This indicates the market value. “Natural exosomes” dominates the type segment of the Europe exosome therapeutic market owing to the increasing chronic conditions. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Europe Exosome Therapeutic Market Scope and Segmentation

Market Definition

The exosomes are a particular class of cell-derived extracellular vesicles composed of endosomes that are normally 30-150 nm in diameter. The exosomes have been connected to treat numerous chronic conditions such as autoimmune disorders. Since the exosomes offer strong potential for applicability in therapeutic interventions, the exosomes have been stated as potential drug carriers. In cancer, exosomes have huge roles in metastatic spread, drug resistance, and the formation of new blood vessels.

Europe Exosome Therapeutic Market Dynamics

Drivers

Increasing Incidence of Cancer

Cancer is a significant health concern worldwide, and Europe is no exception. In recent years, there has been an overall increase in cancer incidence in many European countries. As the population of Europe continues to age, the risk of developing cancer tends to increase. Cancer is more prevalent among older individuals, and as life expectancy increases, so does the likelihood of developing cancer. The prevalence of these risk factors can vary across different European countries, which can impact cancer rates.

Growing R&D Activities Associated with Exosome Research

The growing number of articles associated with exosomal research is enhancing R&D activities in the field. Currently, more than 4400 articles are published on exosomes, with around 25% of these published in 2020 alone. Along with the substantial rise in article publication, the huge range of companies widely engaged in research is also increasing. Additionally, an increase in funding for R&D is set to boost industrial growth positively.

Opportunities

Increasing Developments by Market Players

Major market players have been increasing developments regarding exosome therapeutics, boosting market growth. For instance, Cell Guidance Systems, a U.S.-based biotechnology research organization, declared plans for developing exosome therapeutics for treating COVID-19 disease in 2021. Furthermore, huge growth in government and non-government initiatives for exosome research will most likely enhance the growth during the study period.    

Restraints/Challenges

Contamination Associated with Exosomes

The contamination associated with exosomes leads to market growth reduction. If the exosomes are not properly extracted and sterilized, they can contain intracellular or extracellular genetic material. This genetic material can be very harmful. This can send wrong signals to cells, potentially causing abnormal development of cells at the target site or other areas in the body. Thus, this factor leads to market hindrance.

Recent Developments

• In 2021, Capricor Therapeutics entered into an agreement with Johns Hopkins University to increase the exosome platform technology portfolio. The exosome platform technology portfolio includes engineered exosomes for vaccines and therapeutics as part of the company's exosome technology portfolio. The agreement would enable Capricor Therapeutics to get worldwide right to use exosomes for vaccines and therapeutics.

Europe Exosome Therapeutic Market Scope

The Europe Exosome Therapeutic Market is segmented on the basis of type, source, therapy, transporting capacity, application, route of administration, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Natural
• Hybrid

Source

• Mesenchymal Stem Cells
• Blood, Body Fluids
•  Urine
• Dendritic Cells
• Saliva
• Milk
• Others  

Therapy

• Immunotherapy
• Chemotherapy
• Gene Therapy

Transporting Capacity

• Bio Macromolecules
• Small Molecules

Application

• Metabolic Disorders
• Oncology
• Cardiac Disorders
• Neurology
• Inflammatory Disorders
• Organ Transplantation
• Gynecology Disorders
• Blood Disorders
• Others

Route of Administration

• Parenteral
• Oral

Application

• By Type
• In Vitro Application
• In Vivo Application
• Bioproduction
• Others
• By Industry
• Agriculture
• Synthetic Biology
• Others

End-user

• Research and Academic Institutes
• Hospitals
• Diagnostic Centers

Europe Exosome Therapeutic Market Regional Analysis/Insights

The Europe exosome therapeutic market is analyzed and market size insights and trends are provided by country, type, source, therapy, transporting capacity, application, route of administration, and end user, as referenced above.  

The countries covered in the Europe exosome therapeutic market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, and Rest of Europe.  

Germany is expected to dominate the exosome therapeutic market due to the rising awareness about diseases, the presence of major key players, and the well-developed healthcare infrastructure in this region.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Europe exosome therapeutic market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Europe exosome therapeutic market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Europe exosome therapeutic market. The data is available for the historical period 2012-2022.      

Competitive Landscape and Europe exosome therapeutic market Share Analysis  

The Europe exosome therapeutic market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.  

Some of the major players operating in the Europe exosome therapeutic market are:  

• Boehringer Ingelheim International GmbH (Germany)
• Evox Therapeutics Limited (UK)
• EXOCOBIO (South Korea)
• Exopharm (Australia)
• Creative Medical Technology Holdings, Inc. (US)
• AEGLE Therapeutics (US)
• United Therapeutics Corporation (US)
• Codiak BioSciences (US)
• Jazz Pharmaceuticals, Inc.(Ireland)
• ReNeuron Group plc (UK)
• Capricor Therapeutics (US)
• Avalon Globocare Corp.(US)
• Stem Cells Group (US)